Medindia

X

Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients

Thursday, August 26, 2010 Heart Disease News J E 4
Advertisement
Following Positive Results in Phase I/IIa Dose-Escalation Trial, Cardioxyl Continues to Evaluate Clinical Safety and Tolerability of CXL-1020

(i) Heart Disease and Stroke Statistics 2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119:e1-e161

(ii) Gheorghiade, M. Reassessing treatment of acute heart failure syndromes: the ADHERE Registry. Eur Heart J Suppl.  2005  7: B13-B19

(iii) Jong, P et al. Prognosis and Determinants of Survival in Patients Newly Hospitalized for Heart Failure. Arch Int Med, 2002; 162:1689-1694

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Medisafe 1 Technologies Granted Eligibility Status...
S
DePuy Orthopaedics Voluntarily Recalls ASR™ Hip Sy...